MA-ARTLOGIC
14.10.2021 14:56:08 CEST | Business Wire | Press release
Artlogic, a leader in software solutions for art galleries, collectors, and artists, announced today that it has received a strategic investment from Cove Hill Partners, to support the company in its next phase of growth.
The investment from Cove Hill backs Artlogic in its strong growth trajectory and leadership in the art business software space. Cove Hill’s financial commitment will support innovation and product development, helping Artlogic build on its modern database, CRM, and website products to serve art businesses around the world.
Artlogic will also represent the first company in Cove Hill’s newly founded software holding company, Hive Global, a holding company created by Cove Hill to help scale, support, and invest in modern, market-leading software businesses.
“The Artlogic platform has become an indispensable part of how galleries, artists and collectors run their daily operations, bolstering marketing efforts and accelerating sales. We have been a driving force in ensuring the art world can thrive in an increasingly online-first world, delivering a diverse product suite that gives clients a competitive advantage,” said Joe Elliott, Chief Commercial Officer and Tom Brickman, Chief Creative Officer. “We have enabled art businesses worldwide to bring everything together through our commitment to integration, allowing our clients to focus on what matters most – promoting and selling art.”
“We are thrilled that in Cove Hill we have found an investment partner that is so aligned with our vision and supportive of our culture and values. Their capital, know-how and experience in scaling technology businesses will help us be much more ambitious and serve our growing client base in new and better ways,” said Peter Chater and David Hooper, Founders of Artlogic.
“Cove Hill is excited to partner with the Artlogic management team for the next phase of growth. Artlogic’s cutting edge software provides all the core functionality that art galleries, collectors, and artists need to run their business in a single integrated, best-in-class solution. These capabilities increase efficiency, improve sales and marketing, and simplify database management,” said David Jackson, Co-Founder and Managing Director at Cove Hill. “We believe our investment will allow Artlogic to deliver continued industry leading product innovation and service to its customer base while fueling significant future growth.”
KPMG and Mishcon de Reya advised Artlogic. Choate, Hall & Stewart, Gowling WLG, and PricewaterhouseCoopers represented Cove Hill Partners and Hive Global.
About Artlogic
Founded in 1999, Artlogic provides industry-leading business management software tools for art galleries, collectors, and artists in over 80 countries around the world. Its comprehensive cloud-based platform offers art professionals a 360-degree view of their businesses, allowing them to save time and focus on their work.
About Hive Global
Hive Global is a software holding company founded by Cove Hill Partners in 2021 to invest in market leading software companies globally.
About Cove Hill Partners
Cove Hill Partners is a long-term oriented investment firm focused on partnering with outstanding management teams to build market-leading technology and consumer companies. The firm manages long-duration funds with over $2.5 billion of commitments from its investors and founders. The firm was founded in 2017 by seasoned private equity investors to invest their personal capital alongside a small group of like-minded investors. Based in Boston, Cove Hill has an innovative structure that provides the flexibility to enable a patient, concentrated, and value-add approach in a small portfolio of long-term investments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom